Conversion surgery for tislelizumab combined chemotherapy for T4a/N3 esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study.

Chen Zhang(Shanxi Medical University), Hongjing Jiang(Tianjin Medical University Cancer Institute and Hospital), Fuliang Cao(Tianjin Medical University), Zuoyu Chen(Tianjin Medical University Cancer Institute and Hospital), Shangren Wang(Tianjin Medical University Cancer Institute and Hospital), Yanjuan Xiong(Tianjin Medical University Cancer Institute and Hospital), Runmei Li(Tianjin Medical University Cancer Institute and Hospital), Fan Yang(Gannan Medical University), Jie Yue(Southern Medical University), Jianyu Xiao(Jiangsu Province Blood Center), Chuangui Chen(Tianjin Medical University Cancer Institute and Hospital), Xiaofeng Duan, Liang Liu(Baoding People's Hospital), Weihong Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhao Ma(Tianjin Medical University Cancer Institute and Hospital), Xiubao Ren(Tianjin Medical University Cancer Institute and Hospital), Gang Zhao(Soochow University), Xiaobin Shang(Tianjin Medical University Cancer Institute and Hospital), Feng Guo(Qingdao University of Technology), Dejun Zhou(Henan Polytechnic University)
Journal of Clinical Oncology
June 1, 2024
Cited by 0


Related Papers